CO6280495A2 - Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1 - Google Patents

Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1

Info

Publication number
CO6280495A2
CO6280495A2 CO10087106A CO10087106A CO6280495A2 CO 6280495 A2 CO6280495 A2 CO 6280495A2 CO 10087106 A CO10087106 A CO 10087106A CO 10087106 A CO10087106 A CO 10087106A CO 6280495 A2 CO6280495 A2 CO 6280495A2
Authority
CO
Colombia
Prior art keywords
protein extract
optionally
rpe
ribosomal protein
ribosoma
Prior art date
Application number
CO10087106A
Other languages
English (en)
Spanish (es)
Inventor
Manuel Alvarez
Daniel Abanades
Carlos Alonso Bedate
Original Assignee
Leti S L Unipersonal Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti S L Unipersonal Lab filed Critical Leti S L Unipersonal Lab
Publication of CO6280495A2 publication Critical patent/CO6280495A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO10087106A 2008-01-18 2010-07-16 Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1 CO6280495A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2192808P 2008-01-18 2008-01-18
EP08100634 2008-01-18

Publications (1)

Publication Number Publication Date
CO6280495A2 true CO6280495A2 (es) 2011-05-20

Family

ID=39471089

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10087106A CO6280495A2 (es) 2008-01-18 2010-07-16 Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1

Country Status (19)

Country Link
US (1) US20110020405A1 (enExample)
EP (2) EP2231700B1 (enExample)
JP (2) JP2011509968A (enExample)
CN (1) CN101977930B (enExample)
AP (1) AP3007A (enExample)
AU (1) AU2009204849B2 (enExample)
BR (1) BRPI0906787A2 (enExample)
CA (1) CA2712475A1 (enExample)
CO (1) CO6280495A2 (enExample)
DK (1) DK2231700T3 (enExample)
ES (1) ES2486365T3 (enExample)
HR (1) HRP20140447T1 (enExample)
MA (1) MA32080B1 (enExample)
MX (1) MX2010007831A (enExample)
PL (1) PL2231700T3 (enExample)
PT (1) PT2231700E (enExample)
RU (1) RU2521499C2 (enExample)
WO (1) WO2009090175A1 (enExample)
ZA (1) ZA201005143B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
SG190222A1 (en) 2010-11-10 2013-06-28 Leti Sl Lab New adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
PT1141305E (pt) * 1998-12-23 2006-10-31 Leti Lab Gene quimerico formado pelas sequencias de adn que codifica os determinantes antigenicos de quatro proteinas de l. infantum
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20030072714A1 (en) * 2001-10-12 2003-04-17 Magill Alan J. Microfluidized leishmania lysate and methods of making and using thereof

Also Published As

Publication number Publication date
RU2010134427A (ru) 2012-02-27
JP2015180638A (ja) 2015-10-15
EP2231700B1 (en) 2014-05-07
PL2231700T3 (pl) 2014-09-30
JP2011509968A (ja) 2011-03-31
HRP20140447T1 (hr) 2014-07-04
MA32080B1 (fr) 2011-02-01
AP3007A (en) 2014-10-31
CN101977930A (zh) 2011-02-16
WO2009090175A1 (en) 2009-07-23
CA2712475A1 (en) 2009-07-23
EP2570427A1 (en) 2013-03-20
AP2010005333A0 (en) 2010-08-31
DK2231700T3 (da) 2014-07-14
AU2009204849A1 (en) 2009-07-23
PT2231700E (pt) 2014-07-31
AU2009204849B2 (en) 2013-10-03
MX2010007831A (es) 2011-06-20
US20110020405A1 (en) 2011-01-27
HK1150291A1 (en) 2011-11-18
RU2521499C2 (ru) 2014-06-27
ES2486365T3 (es) 2014-08-18
ZA201005143B (en) 2011-12-28
BRPI0906787A2 (pt) 2015-08-18
EP2231700A1 (en) 2010-09-29
CN101977930B (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CO6331297A2 (es) Composiciones adyuvantes novedosas
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
EA201500432A1 (ru) Соединения боронатного эфира и его фармацевтические составы
MX2016016533A (es) Combinaciones inmunogenas.
ECSP11011367A (es) Composición farmacéutica
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
CR11334A (es) Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado...
AR077987A1 (es) Combinacion farmaceutica que comprende 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol o 6-dimetilaminometil-1-(3-hidroxifenil)-ciclohexano-1,3-diol y un antiepileptico
CO6280495A2 (es) Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
MX2018006026A (es) Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
CO6311109A2 (es) Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso

Legal Events

Date Code Title Description
FC Application refused